Posted by Michael Wonder on 15 Feb 2021
bluebird bio’s beta thalassaemia gene therapy rejected by NICE
12 February 2021 - bluebird bio’s beta thalassaemia gene therapy betibeglogene autotemcel (beti-cel) has not been recommended by the UK’s NICE for use on the NHS.
Beti-cel, marketed as Zynteglo in Europe, is a gene therapy intended for the treatment of transfusion-dependent beta thalassaemia in people aged 12 years and older who do not have a beta0/beta0 genotype.
